[PRNewswire] Abcam completes $340m strategic acquisition and expands kit
전체 맥락을 이해하기 위해서는 본문 보기를 권장합니다.
Alan Hirzel, CEO at Abcam, commented: "We are delighted to welcome our new colleagues to Abcam. Providing a platform for future growth and addition of new product lines, the acquisition of BioVision and expansion of our Eugene facility reinforce our commitment to the acceleration of scientific breakthroughs. Enabling scientists to reproducibly generate the robust results they need, faster, is essential for the delivery of new innovations that can positively impact us all."
본고는 자료 제공사에서 제공한 것으로, 연합뉴스는 내용에 대해 어떠한 편집도 하지 않았음을 밝혀 드립니다.
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
capacity and capability
- Completing $340m strategic acquisition of BioVision
- Expanding facilities in Eugene, further growing kits and assays portfolio
- Supporting the growing demand of the sector and accelerating execution of strategic plan
(CAMBRIDGE, England, Oct. 27, 2021 PRNewswire=연합뉴스) Abcam [https://www.abcamplc.com/ ] (AIM:ABC; NASDAQ: ABCM), a global innovator in life sciences reagents and tools, today announces the successful completion of its acquisition of BioVision and the expansion of its immunoassay capacity in Eugene, OR.
Across the life sciences sector, the events of the last 18 months have amplified the need for efficient workflows and robust data generation, to enable the faster delivery of positive outcomes for science and health. Widespread access to high-performance, reproducible, off-the-shelf assays and kits has become invaluable to enable the biopharma industry and academia to achieve meaningful advances at pace. To further support the growing demand of the sector and to strengthen its position in the assay market, Abcam today announces two significant developments, accelerating the execution of its strategic growth plan.
The addition of BioVision enhances Abcam's in-house innovation and adds scale to support the biochemical assay and cellular assay markets. The successful acquisition brings BioVision's product portfolio, capabilities, and 70-strong expert development and manufacturing teams into Abcam. The global research community will gain ready access to this portfolio of biochemical and cell-based assays via Abcam's global commercialization network.
Supplementing the acquisition, Abcam has doubled the footprint of its immunoassay kit R&D and manufacturing facility in Eugene, OR. This enhanced capacity is another component of Abcam's growth journey in the US and will further enable its commitment to support the research and biopharma sector globally.
Alan Hirzel, CEO at Abcam, commented: "We are delighted to welcome our new colleagues to Abcam. Providing a platform for future growth and addition of new product lines, the acquisition of BioVision and expansion of our Eugene facility reinforce our commitment to the acceleration of scientific breakthroughs. Enabling scientists to reproducibly generate the robust results they need, faster, is essential for the delivery of new innovations that can positively impact us all."
Notes to Editors
About Abcam plc
As a global life sciences company, Abcam identifies, develops, and distributes high-quality biological reagents and tools that are crucial to research, drug discovery and diagnostics. Working across the industry, the Company supports life scientists to achieve their mission, faster.
Abcam partners with life sciences organizations to co-create novel binders for use in drug discovery, in vitro diagnostics and therapeutics, driven by the Company's proprietary discovery platforms and world-leading antibody expertise.
By constantly innovating its binders and assays, Abcam is helping advance the global understanding of biology and causes of disease, which enables new treatments and improved health. The Company's pioneering data-sharing approach gives scientists increased confidence in their results by providing validation, user comments and peer-reviewed citations for its 90,000 products.
With 14 sites globally, many of Abcam's +1,600-strong team are located in the world's leading life sciences research hubs, complementing a global network of services and support.
To find out more, please visit www.abcam.com and www.abcamplc.com.
Logo - https://mma.prnewswire.com/media/1670705/Abcam_Logo.jpg
Abcam Logo
Source: Abcam
[편집자 주] 본고는 자료 제공사에서 제공한 것으로, 연합뉴스는 내용에 대해 어떠한 편집도 하지 않았음을 밝혀 드립니다.
(끝)
출처 : PRNewswire 보도자료
Copyright © 연합뉴스 보도자료. 무단전재 및 재배포 금지.
- [1보] 박하준-금지현 공기소총 10m 혼성 銀…파리올림픽 한국 첫 메달 | 연합뉴스
- [올림픽] 바흐 IOC위원장 "윤 대통령에 개회식 사고 사과하겠다" | 연합뉴스
- 사도광산 세계유산 등재…'韓노동자' 기리는 전시물 현장 설치(종합) | 연합뉴스
- 이재명, 부산 경선서도 92.08% 득표로 압승행진…김두관 7.04% | 연합뉴스
- 내년 의사 국시에 전체 11%인 364명만 접수…의사 배출 '절벽'(종합) | 연합뉴스
- 티몬·위메프 현장 점거 고객들 돌아가…"추가 환불 약속" | 연합뉴스
- '방송4법' 사흘째 필리버스터…與 "나눠먹기 야합" 野 "대안은?" | 연합뉴스
- 100년 만에 다시 파리…첫 수상 개회식 '올림픽의 프랑스 혁명'(종합) | 연합뉴스
- 민주 "이진숙, 법카 유용 의혹 소명 못해…당장 사퇴해야" | 연합뉴스
- 권성동 "김규현-野장경태 접촉해 공작"…張 "제보 확인차였을뿐"(종합) | 연합뉴스